$OPK Cashflow Statement | Understand Stock

$OPK

$1.61 -$0.02 (1.23%) Close

$OPK Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net Income Loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization
Non-cash interest
Amortization of deferred financing costs
Losses from investments in investees
Equity-based compensation – employees and non-employees
Asset impairment charges
Non-cash revenue from the transfer of intellectual property
Impairment charges
Realized loss (gain) on disposal of fixed assets and sales of equity securities
Change in fair value of equity securities and derivative instruments
Loss on conversion convertible senior notes
Inducement expense and loss on debt conversion
Change in fair value of contingent consideration
Deferred income tax provision
Gain on sale of assets

Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net
Inventory, net
Other current assets and prepaid expenses
Other assets
Accounts payable
Foreign currency measurement
Contract liabilities
Accrued expenses and other liabilities
Net cash used in operating activities
Cash flows from investing activities:
Investments in investees
Proceeds from sale of investments
Acquisition of businesses, net of cash acquired
Proceeds from the sale of property, plant and equipment
Capital expenditures
Proceeds from LabCorp Sale
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Issuance of common stock
Issuance of 3.00% convertible senior notes, net (including related parties)
Issuance of 2044 Notes
Debt issuance costs
Share repurchase
Net activity from the exercise of common stock options and warrants
Repurchase of 2029 Convertible Notes
Borrowings on lines of credit
Repayments of lines of credit
Settlement of convertible notes
Redemption of 2025 Notes and 2033 Senior Notes
Net cash (used in) provided by financing activities

Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
SUPPLEMENTAL INFORMATION:
Interest paid
Income taxes paid, net of refunds
Operating lease right-of-use assets due to adoption of ASU No. 2016-02
Operating lease liabilities due to adoption of ASU No. 2016-02
Operating lease right-of-use assets obtained in exchange for lease obligations
Assets acquired by finance leases
Non-cash financing:
2025 convertible Notes
Common Stock options and warrants, surrendered in net exercise
Issuance of common stock for acquisition of ModeX
Fair value of shares included in consideration from GeneDx Holdings

Comments